Global Bio-protein Drug

Bio-protein Drug Comprehensive Study by Type (Monoclonal Antibodies, Recombinant Protein, Therapeutic Proteins, Vaccines), Application (Pharma and Biotech Companies, Clinical Research Organizations, Academics), Treatment (Rheumatoid Arthritis, Inflammatory Bowel Disease, Untreatable Cancer), End User (Hospitals and clinics, Government center, Pharmacy shops) Players and Region - Global Market Outlook to 2026

Bio-protein Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Bio-protein Drug Market Scope?
Bio-Protein drugs are a type of biological product that is used in the prevention, diagnosis, or treatment of cancer and other diseases. There is the use of living organisms for vaccines while other biological drugs produced from proteins are antibodies, therapeutic proteins, engineered proteins, and vaccines. These products are also called biologic agents or biological agents. Recombinant proteins are popularly used to produce pharmaceutical products, protein-based polymers for drug delivery, antibodies and enzymes for disease treatment, protein scaffolds for tissue engineering.

The Bio-protein Drug market study is being classified by Type (Monoclonal Antibodies, Recombinant Protein, Therapeutic Proteins and Vaccines), by Application (Pharma and Biotech Companies, Clinical Research Organizations and Academics) and major geographies with country level break-up.

The biological products are newly emerging in the market as they have the least side effects compared to other chemicals containing drug demand for this product is high. The top leading companies, therefore investing more in their research and development teams for new arrivals and innovations. Also, the companies trying to merge with new ventures and also acquire, who have potential in the market to increase the business and catch the market for a long time.

Abbott Laboratories (United States), Bayer AG (Germany), Eli Lilly and Company (United States), Amgen Inc (United States), Novartis AG (Switzerland), Dr. Reddy's Laboratories (India), Roche (Switzerland), Fresenius Kabi (Germany), GlaxoSmithKline (United Kingdom) and Johnson & Johnson (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Merck (United States), Panacea Biotec (India), ProBioGen AG (Germany), Sanofi (France) and Reliance Life Science Pvt. Ltd (India).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Bio-protein Drug market by Type, Application and Region.

On the basis of geography, the market of Bio-protein Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their development strategies
On 20 February 2020 Lilly Completes Acquisition of Dermira, Eli Lilly and Company announced the successful completion of its acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with the high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. The acquisition of Dermira also expands Lilly's portfolio of marketed dermatology medicines.
On 2nd January 2020 Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China It will Will Accelerate Strategic Collaboration Amgen's Expansion in China. Amgen announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market. BeiGene is a commercial-stage research-based oncology company with an established and highly experienced team in China, including an approximately 900-person commercial organization and an approximately 600-person clinical development organization.
Biological products are regulated by the Food and Drug Administration (FDA) and are used to diagnose, prevent, treat, and cure diseases and medical conditions. Biological products are a diverse category of products and are generally large, complex molecules. These products may be produced through biotechnology in a living system, such as a microorganism, plant cell, or animal cell, and are often more difficult to characterize than small molecule drugs. There are many types of biological products approved for use in the United States, including therapeutic proteins (such as filgrastim), monoclonal antibodies (such as adalimumab), and vaccines (such as those for influenza and tetanus).

Influencing Market Trend
  • Vaccines Are Most Used To Various Diseases

Market Drivers
  • Growing Use Of Immunotherapy Therapy
  • Increasing Awareness About The Benefits Of BioProtein Drug
  • Demanded As It Is Highly Specific In The Treatment

Opportunities
  • Increased Demand In Nano-Particles Drug Delivery
  • Growing Studies And Clinical Trials Ongoing For Various Vaccines

Restraints
  • Problems Like Their Sensitivity To The Physiological Environment, Instability Issues, And Short Half-Life Are Seen
  • A Fully Trained Professional With Strong Technical Knowledge Is Required For Production

Challenges
  • Long Research And Development Procedure Required To Introduces Any New Vaccines, Or Any Other Bio-Protein Drug


Key Target Audience
Manufacturers, Hospital and diagnostic centers, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Clinical Trial Centres and Downstream Vendors

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibodies
  • Recombinant Protein
  • Therapeutic Proteins
  • Vaccines
By Application
  • Pharma and Biotech Companies
  • Clinical Research Organizations
  • Academics
By Treatment
  • Rheumatoid Arthritis
  • Inflammatory Bowel Disease
  • Untreatable Cancer

By End User
  • Hospitals and clinics
  • Government center
  • Pharmacy shops

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Use Of Immunotherapy Therapy
      • 3.2.2. Increasing Awareness About The Benefits Of BioProtein Drug
      • 3.2.3. Demanded As It Is Highly Specific In The Treatment
    • 3.3. Market Challenges
      • 3.3.1. Long Research And Development Procedure Required To Introduces Any New Vaccines, Or Any Other Bio-Protein Drug
    • 3.4. Market Trends
      • 3.4.1. Vaccines Are Most Used To Various Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bio-protein Drug, by Type, Application, Treatment, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Bio-protein Drug (Value)
      • 5.2.1. Global Bio-protein Drug by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Recombinant Protein
        • 5.2.1.3. Therapeutic Proteins
        • 5.2.1.4. Vaccines
      • 5.2.2. Global Bio-protein Drug by: Application (Value)
        • 5.2.2.1. Pharma and Biotech Companies
        • 5.2.2.2. Clinical Research Organizations
        • 5.2.2.3. Academics
      • 5.2.3. Global Bio-protein Drug by: Treatment (Value)
        • 5.2.3.1. Rheumatoid Arthritis
        • 5.2.3.2. Inflammatory Bowel Disease
        • 5.2.3.3. Untreatable Cancer
      • 5.2.4. Global Bio-protein Drug by: End User (Value)
        • 5.2.4.1. Hospitals and clinics
        • 5.2.4.2. Government center
        • 5.2.4.3. Pharmacy shops
      • 5.2.5. Global Bio-protein Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Bio-protein Drug (Price)
      • 5.3.1. Global Bio-protein Drug by: Type (Price)
  • 6. Bio-protein Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dr. Reddy's Laboratories (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Fresenius Kabi (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Bio-protein Drug Sale, by Type, Application, Treatment, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bio-protein Drug (Value)
      • 7.2.1. Global Bio-protein Drug by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Recombinant Protein
        • 7.2.1.3. Therapeutic Proteins
        • 7.2.1.4. Vaccines
      • 7.2.2. Global Bio-protein Drug by: Application (Value)
        • 7.2.2.1. Pharma and Biotech Companies
        • 7.2.2.2. Clinical Research Organizations
        • 7.2.2.3. Academics
      • 7.2.3. Global Bio-protein Drug by: Treatment (Value)
        • 7.2.3.1. Rheumatoid Arthritis
        • 7.2.3.2. Inflammatory Bowel Disease
        • 7.2.3.3. Untreatable Cancer
      • 7.2.4. Global Bio-protein Drug by: End User (Value)
        • 7.2.4.1. Hospitals and clinics
        • 7.2.4.2. Government center
        • 7.2.4.3. Pharmacy shops
      • 7.2.5. Global Bio-protein Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Bio-protein Drug (Price)
      • 7.3.1. Global Bio-protein Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bio-protein Drug: by Type(USD Million)
  • Table 2. Bio-protein Drug Monoclonal Antibodies , by Region USD Million (2015-2020)
  • Table 3. Bio-protein Drug Recombinant Protein , by Region USD Million (2015-2020)
  • Table 4. Bio-protein Drug Therapeutic Proteins , by Region USD Million (2015-2020)
  • Table 5. Bio-protein Drug Vaccines , by Region USD Million (2015-2020)
  • Table 6. Bio-protein Drug: by Application(USD Million)
  • Table 7. Bio-protein Drug Pharma and Biotech Companies , by Region USD Million (2015-2020)
  • Table 8. Bio-protein Drug Clinical Research Organizations , by Region USD Million (2015-2020)
  • Table 9. Bio-protein Drug Academics , by Region USD Million (2015-2020)
  • Table 10. Bio-protein Drug: by Treatment(USD Million)
  • Table 11. Bio-protein Drug Rheumatoid Arthritis , by Region USD Million (2015-2020)
  • Table 12. Bio-protein Drug Inflammatory Bowel Disease , by Region USD Million (2015-2020)
  • Table 13. Bio-protein Drug Untreatable Cancer , by Region USD Million (2015-2020)
  • Table 14. Bio-protein Drug: by End User(USD Million)
  • Table 15. Bio-protein Drug Hospitals and clinics , by Region USD Million (2015-2020)
  • Table 16. Bio-protein Drug Government center , by Region USD Million (2015-2020)
  • Table 17. Bio-protein Drug Pharmacy shops , by Region USD Million (2015-2020)
  • Table 18. South America Bio-protein Drug, by Country USD Million (2015-2020)
  • Table 19. South America Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 20. South America Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 21. South America Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 22. South America Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 23. Brazil Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 24. Brazil Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 25. Brazil Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 26. Brazil Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 27. Argentina Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 28. Argentina Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 29. Argentina Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 30. Argentina Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 31. Rest of South America Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 34. Rest of South America Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 35. Asia Pacific Bio-protein Drug, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 39. Asia Pacific Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 40. China Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 41. China Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 42. China Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 43. China Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 44. Japan Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 45. Japan Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 46. Japan Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 47. Japan Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 48. India Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 49. India Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 50. India Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 51. India Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 52. South Korea Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 53. South Korea Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 54. South Korea Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 55. South Korea Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 56. Taiwan Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 57. Taiwan Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 58. Taiwan Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 59. Taiwan Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 60. Australia Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 61. Australia Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 62. Australia Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 63. Australia Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 68. Europe Bio-protein Drug, by Country USD Million (2015-2020)
  • Table 69. Europe Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 70. Europe Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 71. Europe Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 72. Europe Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 73. Germany Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 74. Germany Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 75. Germany Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 76. Germany Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 77. France Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 78. France Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 79. France Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 80. France Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 81. Italy Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 82. Italy Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 83. Italy Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 84. Italy Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 85. United Kingdom Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 88. United Kingdom Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 89. Netherlands Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 90. Netherlands Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 91. Netherlands Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 92. Netherlands Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 93. Rest of Europe Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 96. Rest of Europe Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 97. MEA Bio-protein Drug, by Country USD Million (2015-2020)
  • Table 98. MEA Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 99. MEA Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 100. MEA Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 101. MEA Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 102. Middle East Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 103. Middle East Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 104. Middle East Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 105. Middle East Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 106. Africa Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 107. Africa Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 108. Africa Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 109. Africa Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 110. North America Bio-protein Drug, by Country USD Million (2015-2020)
  • Table 111. North America Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 112. North America Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 113. North America Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 114. North America Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 115. United States Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 116. United States Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 117. United States Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 118. United States Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 119. Canada Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 120. Canada Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 121. Canada Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 122. Canada Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 123. Mexico Bio-protein Drug, by Type USD Million (2015-2020)
  • Table 124. Mexico Bio-protein Drug, by Application USD Million (2015-2020)
  • Table 125. Mexico Bio-protein Drug, by Treatment USD Million (2015-2020)
  • Table 126. Mexico Bio-protein Drug, by End User USD Million (2015-2020)
  • Table 127. Bio-protein Drug: by Type(USD/Units)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Bio-protein Drug: by Type(USD Million)
  • Table 139. Bio-protein Drug Monoclonal Antibodies , by Region USD Million (2021-2026)
  • Table 140. Bio-protein Drug Recombinant Protein , by Region USD Million (2021-2026)
  • Table 141. Bio-protein Drug Therapeutic Proteins , by Region USD Million (2021-2026)
  • Table 142. Bio-protein Drug Vaccines , by Region USD Million (2021-2026)
  • Table 143. Bio-protein Drug: by Application(USD Million)
  • Table 144. Bio-protein Drug Pharma and Biotech Companies , by Region USD Million (2021-2026)
  • Table 145. Bio-protein Drug Clinical Research Organizations , by Region USD Million (2021-2026)
  • Table 146. Bio-protein Drug Academics , by Region USD Million (2021-2026)
  • Table 147. Bio-protein Drug: by Treatment(USD Million)
  • Table 148. Bio-protein Drug Rheumatoid Arthritis , by Region USD Million (2021-2026)
  • Table 149. Bio-protein Drug Inflammatory Bowel Disease , by Region USD Million (2021-2026)
  • Table 150. Bio-protein Drug Untreatable Cancer , by Region USD Million (2021-2026)
  • Table 151. Bio-protein Drug: by End User(USD Million)
  • Table 152. Bio-protein Drug Hospitals and clinics , by Region USD Million (2021-2026)
  • Table 153. Bio-protein Drug Government center , by Region USD Million (2021-2026)
  • Table 154. Bio-protein Drug Pharmacy shops , by Region USD Million (2021-2026)
  • Table 155. South America Bio-protein Drug, by Country USD Million (2021-2026)
  • Table 156. South America Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 157. South America Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 158. South America Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 159. South America Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 160. Brazil Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 161. Brazil Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 162. Brazil Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 163. Brazil Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 164. Argentina Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 165. Argentina Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 166. Argentina Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 167. Argentina Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 168. Rest of South America Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 169. Rest of South America Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 170. Rest of South America Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 171. Rest of South America Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 172. Asia Pacific Bio-protein Drug, by Country USD Million (2021-2026)
  • Table 173. Asia Pacific Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 174. Asia Pacific Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 175. Asia Pacific Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 176. Asia Pacific Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 177. China Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 178. China Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 179. China Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 180. China Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 181. Japan Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 182. Japan Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 183. Japan Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 184. Japan Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 185. India Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 186. India Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 187. India Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 188. India Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 189. South Korea Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 190. South Korea Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 191. South Korea Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 192. South Korea Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 193. Taiwan Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 194. Taiwan Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 195. Taiwan Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 196. Taiwan Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 197. Australia Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 198. Australia Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 199. Australia Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 200. Australia Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 205. Europe Bio-protein Drug, by Country USD Million (2021-2026)
  • Table 206. Europe Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 207. Europe Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 208. Europe Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 209. Europe Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 210. Germany Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 211. Germany Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 212. Germany Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 213. Germany Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 214. France Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 215. France Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 216. France Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 217. France Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 218. Italy Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 219. Italy Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 220. Italy Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 221. Italy Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 222. United Kingdom Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 223. United Kingdom Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 224. United Kingdom Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 225. United Kingdom Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 226. Netherlands Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 227. Netherlands Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 228. Netherlands Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 229. Netherlands Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 230. Rest of Europe Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 231. Rest of Europe Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 232. Rest of Europe Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 233. Rest of Europe Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 234. MEA Bio-protein Drug, by Country USD Million (2021-2026)
  • Table 235. MEA Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 236. MEA Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 237. MEA Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 238. MEA Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 239. Middle East Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 240. Middle East Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 241. Middle East Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 242. Middle East Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 243. Africa Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 244. Africa Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 245. Africa Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 246. Africa Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 247. North America Bio-protein Drug, by Country USD Million (2021-2026)
  • Table 248. North America Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 249. North America Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 250. North America Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 251. North America Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 252. United States Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 253. United States Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 254. United States Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 255. United States Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 256. Canada Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 257. Canada Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 258. Canada Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 259. Canada Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 260. Mexico Bio-protein Drug, by Type USD Million (2021-2026)
  • Table 261. Mexico Bio-protein Drug, by Application USD Million (2021-2026)
  • Table 262. Mexico Bio-protein Drug, by Treatment USD Million (2021-2026)
  • Table 263. Mexico Bio-protein Drug, by End User USD Million (2021-2026)
  • Table 264. Bio-protein Drug: by Type(USD/Units)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bio-protein Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Bio-protein Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Bio-protein Drug: by Treatment USD Million (2015-2020)
  • Figure 7. Global Bio-protein Drug: by End User USD Million (2015-2020)
  • Figure 8. South America Bio-protein Drug Share (%), by Country
  • Figure 9. Asia Pacific Bio-protein Drug Share (%), by Country
  • Figure 10. Europe Bio-protein Drug Share (%), by Country
  • Figure 11. MEA Bio-protein Drug Share (%), by Country
  • Figure 12. North America Bio-protein Drug Share (%), by Country
  • Figure 13. Global Bio-protein Drug: by Type USD/Units (2015-2020)
  • Figure 14. Global Bio-protein Drug share by Players 2020 (%)
  • Figure 15. Global Bio-protein Drug share by Players (Top 3) 2020(%)
  • Figure 16. Global Bio-protein Drug share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 20. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 22. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 24. Amgen Inc (United States) Revenue, Net Income and Gross profit
  • Figure 25. Amgen Inc (United States) Revenue: by Geography 2020
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 29. Dr. Reddy's Laboratories (India) Revenue: by Geography 2020
  • Figure 30. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Roche (Switzerland) Revenue: by Geography 2020
  • Figure 32. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Fresenius Kabi (Germany) Revenue: by Geography 2020
  • Figure 34. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 36. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 37. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 38. Global Bio-protein Drug: by Type USD Million (2021-2026)
  • Figure 39. Global Bio-protein Drug: by Application USD Million (2021-2026)
  • Figure 40. Global Bio-protein Drug: by Treatment USD Million (2021-2026)
  • Figure 41. Global Bio-protein Drug: by End User USD Million (2021-2026)
  • Figure 42. South America Bio-protein Drug Share (%), by Country
  • Figure 43. Asia Pacific Bio-protein Drug Share (%), by Country
  • Figure 44. Europe Bio-protein Drug Share (%), by Country
  • Figure 45. MEA Bio-protein Drug Share (%), by Country
  • Figure 46. North America Bio-protein Drug Share (%), by Country
  • Figure 47. Global Bio-protein Drug: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Bayer AG (Germany)
  • Eli Lilly and Company (United States)
  • Amgen Inc (United States)
  • Novartis AG (Switzerland)
  • Dr. Reddy's Laboratories (India)
  • Roche (Switzerland)
  • Fresenius Kabi (Germany)
  • GlaxoSmithKline (United Kingdom)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Merck (United States) , Panacea Biotec (India) , ProBioGen AG (Germany) , Sanofi (France) , Reliance Life Science Pvt. Ltd (India)
Select User Access Type

Key Highlights of Report


Sep 2021 233 Pages 57 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bio-protein Drug Quantitative research analysis
Global Bio-protein Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Bio-protein Drug market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Bio-protein Drug market are Abbott Laboratories (United States), Bayer AG (Germany), Eli Lilly and Company (United States), Amgen Inc (United States), Novartis AG (Switzerland), Dr. Reddy's Laboratories (India), Roche (Switzerland), Fresenius Kabi (Germany), GlaxoSmithKline (United Kingdom) and Johnson & Johnson (United States), to name a few.
In this highly competitive & fast evolving Bio-protein Drug industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Bio-protein Drug Report?

Have a Query? Click Here

Other Related Reports

Sumatriptan Succinate Comprehensive Study by Application (Migraine, Cluster Headache), Mode Of Administration (Oral, Subcutaneous Injection), Form (Tablet, Injection, Spray), Distribution Channel (On...
$ 3450
Biopharmaceutical Logistics - Comprehensive Study by Type (Cold-chain Transport, Non-Cold-chain Transport.), Storage (Storage, Transportation, Monitoring Components), Transportation (Air Shipping, Ra...
$ 3650
Antimicrobial Gel Comprehensive Study by Type (Silver Antimicrobial Gel, Iodine Antimicrobial Gel, Others), Application (Home Use, Hospital Use), Distribution Channel (Hospital Pharmacies, Retail Pha...
$ 3350
Iloprost Drugs Comprehensive Study by Type (OTC, Prescribed), Application (Pulmonary Arterial Hypertension (PAH), High Blood Pressure), Route of Administration (Intravenous, Respiratory (Inhalation))...
$ 3450
Granisetron Comprehensive Study by Application (Chemotherapy, Radiotherapy, Nausea, Gastroparesis, Postoperative), Forms (Injection, Tablet, Syrup, Tablet, Oral Drops), Drug type (Generic drug, Paten...
$ 3350
Digital Diabetes Management Comprehensive Study by Type (Devices, Digital Diabetes Apps, Data Management Software and Platforms), Device Type (Wearable Devices, Handheld Devices), End User (Self/Home...
$ 3450